Posted by Michael Wonder on 26 May 2017
CalciMedica receives fast-track designation for CM4620, a novel CRAC channel inhibitor to treat acute pancreatitis
24 May 2017 - Patient studies expected to begin in 2018.
CalciMedica announced today that it received fast-track designation from the U.S. FDA for its lead clinical compound, CM4620, a novel, calcium release-activated calcium (CRAC) channel inhibitor, for the treatment of acute pancreatitis.
Currently, there are no therapeutic agents approved to treat acute pancreatitis, an inflammatory condition that is the leading cause of gastrointestinal hospitalisations and healthcare cost burden in the US.
